iXensor Receives Strategic Investment from Rohto Pharmaceutical with A Separate Technology Licensing Agreement
iXensor Co., Ltd. (6734. TWO)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005097/en/
iXensor Receives Strategic Investment from Rohto Pharmaceutical with A Separate Technology Licensing Agreement
iXensor, the pioneer of mobile health, today announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business.
Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech® technology to digitize its new products through a separate technology licensing and joint development agreement, thereby providing Rohto Pharmaceutical's consumers with innovative self-testing portfolios including women's health and infectious diseases in Japan market.
iXensor's first product, PixoTest® Glucose Monitoring System, developed based on its PixoTech® platform, is the world's first US FDA-approved smartphone camera-based blood test dated in 2017. The PixoTech®, currently protected by more than 70 international patents, is iXensor's core technology platform that transforms smartphones into in vitro diagnostic instruments for biomedical analysis in point-of-care testing and self-testing. PixoTech® controls smartphones' camera sensing modules and screen lighting emissions with multiple wavelengths to analyze all types of immunoassay and enzymatic tests through the proprietary algorithm.
Mr. Hidetoshi Segi, Chief Strategy Officer of Rohto Pharmaceutical, commented, "By investing in iXensor, we can deepen our joint efforts on a series of new product developments, thus expanding our testing and diagnostic business through a wave of digital transformation. As the first step, we will receive a technical license for smartphone-based diagnostic devices and apps from iXensor to develop and sell innovative self-testing products."
Dr. Carson Chen, CEO of iXensor, expressed, "This partnership represents the unlimited potential and technical advantage of the PixoTech® platform to transform smartphones into precision medical diagnostic devices. The licensing business of PixoTech® technology started shifting in as the new engine to drive iXensor's growth."
In the post-pandemic era, iXensor endeavors to accelerate the growth of the at-home self-testing market and empower the evolution of the digital health ecosystem through licensing the PixoTech® technology. Thanks to that, PixoTech® can be flexibly applied to the digitalization of various lateral flow tests. In addition, it can shorten the lead time for IVD manufacturers venturing into the digital health business. It can also be applied to develop companion diagnostic or remote monitoring tools for pharmaceuticals to prove the efficacy of new classes of medications with actual test results collected from patients' smartphones with comfort at home.
About Rohto Pharmaceutical
Founded in 1899, Rohto Pharmaceutical is a renowned Japanese company that has successfully commercialized its research and development of consumer and pharmaceutical products worldwide. Rohto Pharmaceutical has established a robust product portfolio, including eye care, skincare, gastrointestinal medicines, and functional foods. Within the test drug business, the novel coronavirus antigen rapid test for medical institutions was launched in response to the global epidemic in addition to the existing pregnancy test, ovulation test, and flu rapid test products.
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, diabetes, and cardiovascular diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005097/en/
Contact information
Media Contact
Spokesperson: Patrick Liao
Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-928-570-208
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“e4life” is Present at Expomed Eurasia with its Innovative Device Able to Inactivate Flu and Covid Viruses With an Efficacy over 90%19.4.2024 17:13:00 CEST | Press release
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419226980/en/ e4life: e4ambient and e4you devices (Photo: Business Wire) This is a perfect occasion for e4life to present its device based on the e4shield technology which is able to inactivate flu and Covid viruses present in the air. A technology, patented in Italy, that uses neither chemical agents nor filtering materials, but it is based on the transmission of electromagnetic waves able to inactivate the viral load in aerosol. “This Exhibition represents an extraordinary opportunity to present our innovative technology (e4shield) in a dynamic and rapidly evolving region as Eurasia. In a climate of growing consciousness of the
Qualcomm Schedules Second Quarter Fiscal 2024 Earnings Release and Conference Call19.4.2024 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its second quarter fiscal 2024 on Wednesday, May 1, 2024, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its second quarter fiscal 2024 results which will be broadcast live on May 1, 2024, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/events. An audio replay will be available at https://investor.qualcomm.com/news-events/events and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers may dial (201) 612-7415. Callers should use rese
Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer19.4.2024 14:56:00 CEST | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today announced the appointment of Francois Hardy as Chief Technology Officer (CTO). Francois will join Newmont’s Executive Leadership Team and lead the technical work across the business to improve operational performance and drive growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419973025/en/ Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer (Photo: Business Wire) Francois will take over from interim CTO, Dean Gehring, who also served in a dual role as Newmont’s Chief Integration Officer. After a period of transition, Dean will be leaving the company in early July. Francois brings more than 30 years of technical and operational experience in mining to the role. He commenced with Newmont in 2002 and has held roles including Group Head Exploration, Managing Director Africa and General Manager Tanami. “Francois is a stron
SLB Announces First-Quarter 2024 Results, Targeting to Return $7 Billion to Shareholders Over 2024–202519.4.2024 12:50:00 CEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417469361/en/ The exterior of the SLB headquarters in Houston, Texas (Photo: Business Wire) First-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeMar. 31, 2024Dec. 31, 2023Mar. 31, 2023 SequentialYear-on-yearRevenue $8,707 $8,990 $7,736 -3% 13% Income before taxes - GAAP basis $1,357 $1,433 $1,161 -5% 17% Income before taxes margin - GAAP basis 15.6% 15.9% 15.0% -35 bps 58 bps Net income attributable to SLB - GAAP basis $1,068 $1,113 $934 -4% 14% Diluted EPS - GAAP basis $0.74 $0.77 $0.65 -4% 14% Adjusted EBITDA* $2,057 $2,277 $1,788 -10% 15% Adjusted EBITDA margin* 23.6% 25.3% 23.1% -171 bps 51 bps Pretax segment operating income* $1,649 $1,868 $1,391 -12% 19% Pretax segment operating margin* 18.9% 20.8% 18.0% -184 bps 95 bps Net income attributable to SLB, excluding cha
Zayo Group Appoints New CEO of Zayo Europe19.4.2024 09:00:00 CEST | Press release
Zayo Group, a leading global provider of network infrastructure, has appointed Colman Deegan as its new CEO of Zayo Europe to drive the business’ growth as cloud and AI adoption continues across the continent. This appointment is effective as of April 16, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419471253/en/ Colman Deegan, CEO Zayo Europe (Photo: Business Wire) Steve Smith, CEO Zayo Group, says, “Colman’s experience and proven track record as a CEO leading large teams and businesses makes him perfectly equipped to take our European business to new heights, together with our outstanding local team. Colman will drive Zayo forward, strengthening our partnerships with data centres, hyperscalers, and enterprises across Europe. Under Colman’s leadership, we are confident that we will achieve our bold ambitions and maximise our impact in the European market.” Deegan spent more than two decades at Vodafone where he h
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom